Effects of lactational exposure of olanzapine and risperidone on hematology and lymphoid organs histopathology: A comparative study in mice neonates

European Journal of Pharmacology

Volumn 634, Issue 1-3, 2010, Pages 170-177

  Mishra, Akash C ^a   Mohanty, Banalata ^a  

^a UNIVERSITY OF ALLAHABAD   (India)

Author keywords

Atypical antipsychotics; Lactational exposures; Lymphoid organ histopathology; Mice neonates; Neutropenia

Indexed keywords

OLANEX; OLANZAPINE; RESPIDON; RISPERIDONE; UNCLASSIFIED DRUG; BENZODIAZEPINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD TOXICITY; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DOSE RESPONSE; DRUG DOSE COMPARISON; FEMALE; HISTOPATHOLOGY; IMMUNE DYSREGULATION; LACTATION; LEUKOCYTE DIFFERENTIAL COUNT; LYMPHATIC SYSTEM DISEASE; MOUSE; NEUTROPENIA; NEWBORN; NONHUMAN; ORGAN WEIGHT; PERINATAL DRUG EXPOSURE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; THYMUS; ANIMAL; CHEMICALLY INDUCED; COMPARATIVE STUDY; DRUG EFFECTS; HEMATOLOGIC DISEASE; HYPERPROLACTINEMIA; MALE; METABOLISM; PATHOLOGY; SPLEEN; TOXICITY;

ANIMALS; ANIMALS, NEWBORN; BENZODIAZEPINES; FEMALE; HEMATOLOGIC DISEASES; HYPERPROLACTINEMIA; LACTATION; MALE; MICE; RISPERIDONE; SPLEEN; THYMUS GLAND;

EID: 77951205450     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.02.014     Document Type: Article

References (58)

1. Abdullah N., Voronovitch L., Taylor S., Lippmann S. Olanzapine and Haloperidol: Potential for Neutropenia?. Psychosomatics 2003, 44:83-84.
2. Assié M.B., Carilla-Durand E., Bardin L., Maraval M., Aliaga M., Malfètes N., Barbara M., Newman-Tancredi A. The antipsychotics clozapine and olanzapine increase plasma glucose and corticosterone levels in rats: Comparison with aripiprazole, ziprasidone, bifeprunox and F15063. Eur. J. Pharmacol. 2008, 592:160-166.
3. Baptista T., Araujo de Baptista E., Ying Kin N.M., Beaulieu S., Walker D., Joober R., Lalonde J., Richard D. Comparative effects of the antipsychotics sulpiride or risperidone in rats. I: bodyweight, food intake, body composition, hormones and glucose tolerance. Brain Res. 2002, 957:144-151.
4. Besedovsky H.O., Rey A.D. Physiology of psychoneuroimmunology: a personal view. Brain Behav. Immun. 2007, 21:34-44.
5. Bhana N., Foster R.H., Plosker O., Plosker G.L. Olanzapine: an updated review of its use in the management of schizophrenia. Drugs 2001, 61:111-161.
6. Bubeníková V., Votava M., Horáček J., Páleníček T., Dockery C. The effect of zotepine, risperidone, clozapine and olanzapine on MK-801-disrupted sensorimotor gating. Pharmacol. Biochem. Behav. 2005, 80:591-596.
7. Byerlya M.J., Nakoneznyb P.A., Bettchera B.M., Carmodyb T., Fishera R., Ruschc A.J. Sexual dysfunction associated with second-generation antipsychotics in outpatients with schizophrenia or schizoaffective disorder: An empirical evaluation of olanzapine, risperidone, and quetiapine. Schizophr. Res. 2006, 86:244-250.
8. Cadario, B., 2000. Olanzapine (Zyprexa): suspected serious reactions. C.M.A.J. 163, 85-86, 89-90.
9. Contesse V., Lefebvre H., Lenglet S., Kuhn J.M., Delarue C., Vaudry H. Role of 5-HT in the regulation of the brain-pituitary-adrenal axis: effects of 5-HT on adrenocortical cells. Can. J. Physiol. Pharmacol. 2000, 78:967-983.
10. Corzo D., Yunis J.J., Salazar M., Lieberman J.A., Howard A., Awdeh Z., Alper C.A., Yunis E.J. The major histocompatibility complex region marked by HSP70-1 and HSP70-2 variants is associated with clozapine-induced agranulocytosis in two different ethnic groups. Blood 1995, 86:3835-3840.
11. Cutler A.J. Sexual dysfunction and antipsychotic treatment. Psychoneuroendocrinology 2003, 28:69-82.
12. Delieu J.M., Horobin R.W., Duguid J.K. Formation of immature neutrophil leukocytes in schizophrenic patients treated with various antipsychotic drugs: comparisons and predictions. J. Psychopharmacol. 2006, 20:824-828.
13. Delieu J.M., Horobin R.W., Duguid J.K. Exploring the relationship of drug-induced neutrophil immaturity & haematological toxicity to drug chemistry using quantitative structure-activity models. Med. Chem. 2009, 5:7-14.
14. Dernovsek M.J., Tavear R. Olanzapine appears haematologically safe in patients who developed blood dichasia on clozapine and risperidone. Int. Clin. Psychopharmacol. 2000, 15:237-238.
15. Eichhorst S.T., Muerkoster S., Weigand M.A., Krammer P.H. The Chemotherapeutic Drug 5-Fluorouracil Induces Apoptosis in Mouse Thymocytes in Vivo via Activation of the CD95 (APO-1/Fas) System. Cancer Res. 2001, 61:243-248.
16. Elmore S.A. Enhanced Histopathology of the Thymus. Toxicol. Pathol. 2006, 34:656-665.
17. Finkel B., Lerner A., Oyffe I. Olanzapine treatment in patients with typical and atypical Neuroleptic-associated agranulocytosis. Int. Clin. Psychopharmacol. 1998, 13:133-135.
18. Gajwani P., Tesar G.E. Olanzapine-Induced Neutropenia. Psychosomatics 2000, 41:150-151.
19. Gardiner S.J., Kristensen J.H., Hackett L.P., Ilett K.F., Rampono J. Transfer of olanzapine into breast milk calculation of infant drug dose and effect on breast fed infants. Am. J. Psychiatry 2003, 160:1428-1431.
20. Gerli R., Riccardi C., Nicoletti I., Orlandi S., Cernetti C., Spinozzi F., Rambotti P. Phenotypic and functional abnormalities of T lymphocytes in pathological hyperprolactinemia. J. Clin. Immunol. 1987, 7:463-470.
21. Gerez J., Bonfiglio J., Sosa S., Giacomini D., Acuna M., Nagashima A.C., Perone M.J., Silberstein S., Renner U., Stalla G.K., Arzt E. Molecular transduction mechanisms of cytokine-hormone interactions: role of gp130 cytokines. Exp. Physiol. 2007, 92.5:801-806.
22. Goldstein D.J., Gorbin I.A., Fung M.C. Olanzapine exposed pregnancies and lactation: early experience. J. Clin. Psychopharmacol. 2000, 20:399-403.
23. Ilett K.F., Hackett L.P., Kristensen J.H., Vaddadi K.S., Gardiner S.J., Begg E.J. Transfer of risperidone and 9-hydroxy risperidone into human milk. Ann. Pharmacother. 2004, 38:273-276.
24. Jayaram M.B., Hosalli P., Stroup T.S. Risperidone versus olanzapine for treatment of schizophrenia. Schizophr. Bull. 2007, 33:1274-1276.
25. Kapur S., Zipursky R.B., Remington G., Jones C., DaSilva J., Wilson A.A., Houle S. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am. J. Psychiatry 1998, 155:928-931.
26. Kapur S., Vanderspek S.C., Brownlee B.A., Nobrega J.N. Antipsychotic dosing in preclinical models is often unrepresentative of the clinical conditions: A suggested solution based on in vivo occupancy new hypothesis. J. Pharmacol. Exp. Ther. 2003, 305:625-631.
27. Kinon B.J., Ahl J., Liu-Seifert H., Maguire G.A. Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine. Psychoneuroendocrinology 2006, 31:577-588.
28. Knegtering H., Vandermoolen A.E., Castelein S., Kluiter H., Vanderbosch R.J. What are the effects of antipsychotics on sexual dysfunction and endocrine functioning?. Psychoneuroendocrinology 2003, 28:109-123.
29. Konarzewska B., Wołczyński S., Szulc A., Galińska B., Popławska R., Waszkiewicz N. Effect of risperidone and olanzapine on reproductive hormones, psychopathology and sexual functioning in male patients with schizophrenia. Psychoneuroendocrinology 2009, 34:129-139.
30. Lieberman J.A., Tasman A. Handbook of Psychiatric Drugs 2006, 264. John Wiley and Sons Ltd, USA.
31. Maggs J.L., Williams D., Pirmohamed M., Park B.K. The metabolic formation of reactive intermediates from clozapine, a drug associated with agranulocytosis in man. J. Pharmacol. Exp. Ther. 1995, 275:1463-1475.
32. Marx C.E., VanDoren M.J., Duncan G.E., Lieberman J.A., Morrow A.L. Olanzapine and clozapine increase the GABAergic neuroactive steroid allopregnanolone in rodents. Neuropsychopharmacology 2003, 28:1-13.
33. Matera L. Action of Pituitary and Lymphocyte Prolactin. Neuroimmunomodulation 1997, 4:171-180.
34. McMurray R.W. Prolactin in murine systemic lupus erythematosus. Lupus 2001, 10:742-747.
35. Mishra A.C., Mohanty B. Effect of lactational olanzapine exposure on body weight of mice: A comparative study on neonates of both the sexes during post-natal development. J. Psychopharmacol 2009, 10.1177/0269881108100775.
36. Mishra, A.C., Mohanty, B., in press. Lactational exposure to atypical antipsychotic drugs disrupt pituitary-testicular axis in mice neonates during post-natal development. J. Psychopharmacol. doi:10.1177/0269881109348162.
37. Orbach H., Shoenfeld Y. Hyperprolactinemia and autoimmune diseases. Autoimmun. Rev. 2007, 6:537-542.
38. Oyesanmi O., Kunkel E.J.S., Monti D.A., Field H.L. Hematologic side effects of Psychotropics. Psychosomatics 1999, 40:414-421.
39. Pessina A., Turlizzi E., Bonomi A., Guizzardi F., Cavicchini L., Croera C., Bareggi S. In vitro toxicity of clozapine, olanzapine, and quetiapine on granulocyte-macrophage progenitors (GM-CFU). Pharmacopsychiatry 2006, 39:20-22.
40. Pirmohamed M., Park B.K. Mechanism of action of clozapine-induced agranulocytosis: current status of research and implications for drug development. Cent. Nerv. Syst. Drugs 1997, 7:138-158.
41. Raanani P., Ben-Bassat I. Immune-Mediated Complications during Interferon Therapy in Hematological Patients. Acta Haematol. 2002, 107:133-144.
42. Robinson D.S. Psychopharmacology Research Tutorial for Practitioners - Clozapine Agranulocytosis: Mechanism of Drug Toxicity. Prim. Psychiatry 2006, 13:27-29.
43. Rourke C., Starr K.R., Reavill C., Fenwick S., Deadman K., Jones D.N.C. Effects of the atypical antipsychotic olanzapine and risperidone on plasma prolactin levels in male rats: a comparison with clinical data. Psychopharmacology 2006, 184:107-114.
44. Ruzek M.C., Hawes M., Pratt B., McPherson J., Ledbetter S., Richards S.M., Garman R.D. Minimal Effects on Immune Parameters Following Chronic Anti-TGF-β Monoclonal Antibody Administration to Normal Mice. Immunopharmacol. Immunotoxicol. 2005, 25:235-257.
45. Sayin A., Cosar B. Prolongation of clozapine-induced leukopenia with olanzapine treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry 2006, 30:958-959.
46. Schotte A., Janssen P.F., Gommeren W., Luyten W.H., Van Gompel P., Lesage A.S., De Loore K., Leysen J.E. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 1996, 124:57-73.
47. Stergiou V., Bozikas V.P., Garyfallos G., Nikolaidis N., Lavrentiadis G., Fokas K. Olanzapine-induced leucopenia and neutropenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2005, 29:865-1100.
48. Tu C.H., Yang S. Olanzapine-induced EDTA- Dependent pseudothrombocytopoenia. Psychosomatics 2002, 43:421-423.
49. Turbay D., Lieberman J., Alper C.A., Delgado J.C., Corzo D., Yunis J.J., Yunis E.J. Tumor necrosis factor constellation polymorphism and clozapine-induced agranulocytosis in two different ethnic groups. Blood 1997, 89:4167-4174.
50. Uetrecht J.P. Metabolism of clozapine by neutrophils. Possible implications for clozapine-induced agranulocytosis. Drug Saf. 1992, 7:51-56.
51. van Bruggen M., Amelsvoort T., Wouters L., Dingemans P., Haan L., Linszen D. Sexual dysfunction and hormonal changes in first episode psychosis patients on olanzapine or risperidone. Psychoneuroendocrinology 2009, 34:989-995.
52. Vidaller A., Llorente L., Larrea F., Mendez J.P., Alcocer-Varela J., Alarcon-Segovia D. T-cell dysregulation in patients with hyperprolactinemia: effect of bromocriptine treatment. Clin. Immunol. Immunopathol. 1986, 38:337-343.
53. Vidaller A., Guadarrama F., Llorente L., Mendez J.B., Larrea F., Villa A.R., Alarcon-Segovia D. Hyperprolactinemia inhibits natural killer (NK) cell function in vivo and its bromocriptine treatment not only corrects it but makes it more efficient. J. Clin. Immunol. 1992, 12:210-215.
54. Webster J.I., Tonelli, l., Sternberg E.M. Neuroendocrine regulation of immunity. Annu. Rev. Immunol. 2002, 20:125-163.
55. Williams D.P., Pirmohamed M., Naisbitt D.J., Maggs J.L., Park B.K. Neutrophil cytotoxicity of the chemically reactive metabolite(s) of clozapine: possible role in agranulocytosis. J. Pharmacol. Exp. Ther. 1997, 283:1375-1382.
56. Williams D.P., Pirmohamed M., Naisbitt D.J., Uetrecht J.P., Park B.K. Induction of metabolism-dependent and independent neutrophil apoptosis by clozapine. Mol. Pharmacol. 2000, 58:207-216.
57. Wudarsky M., Nicolson R., Hamburger S.D., Spechler L., Gochman P., Bedwell J., Lenane M.C., Rapoport J.L. Elevated prolactin in pediatric patients on typical and atypical antipsychotics. J. Child Adolesc. Psychopharmacol. 1999, 9:239-245.
58. Yunis J.J., Corzo D., Salazar M., Lieberman J.A., Howard A., Yunis E.J. HLA associations in clozapine-induced agranulocytosis. Blood 1995, 86:1177-1183.